Christopher R. Fenimore
Known title: SVP ControllerCIK: 0001697422
Associated companies
Transaction History
| REGN | ▲ Buy | Option Exercise | 6,283 | $2.4M | 8/18/2026 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 4,599 | $3.7M | 8/18/2026 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 992 | $707K | 12/8/2025 | View on chart |
| REGN | ▲ Buy | Grant | 3,027 | $0 | 12/5/2025 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 491 | $359K | 12/16/2024 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 1,140 | $897K | 12/9/2024 | View on chart |
| REGN | ▲ Buy | Grant | 2,591 | $0 | 12/6/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 200 | $241K | 8/28/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 200 | $241K | 8/28/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 228 | $275K | 8/28/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 236 | $285K | 8/28/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 450 | $543K | 8/28/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 766 | $923K | 8/28/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 2,237 | $2.7M | 8/28/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 235 | $283K | 8/28/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 928 | $1.1M | 8/28/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 200 | $241K | 8/28/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 487 | $463K | 2/9/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 344 | $327K | 2/9/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 1,342 | $1.3M | 2/9/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 1,100 | $1.1M | 2/9/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 600 | $573K | 2/9/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 1,046 | $996K | 2/9/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 5,000 | $2.8M | 1/23/2024 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 3,986 | $3.8M | 1/23/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 5,000 | $2.0M | 1/23/2024 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 3,583 | $3.4M | 1/23/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 5,000 | $2.8M | 1/3/2024 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 3,469 | $3.2M | 1/3/2024 | View on chart |
| REGN | ▲ Buy | Option Exercise | 5,000 | $2.0M | 1/3/2024 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 4,043 | $3.7M | 1/3/2024 | View on chart |
| REGN | ▼ Sell | Open Market | 2,448 | $2.1M | 12/27/2023 | View on chart |
| REGN | ▼ Sell | Open Market | 250 | $212K | 12/22/2023 | View on chart |
| REGN | ▼ Sell | Open Market | 1,224 | $1.0M | 12/21/2023 | View on chart |
| REGN | ▼ Sell | Open Market | 456 | $385K | 12/21/2023 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 2,552 | $2.2M | 12/12/2023 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 260 | $219K | 12/11/2023 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 1,276 | $1.1M | 12/11/2023 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 474 | $400K | 12/8/2023 | View on chart |
| REGN | ▲ Buy | Grant | 2,370 | $0 | 12/8/2023 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 5,198 | $4.4M | 8/23/2023 | View on chart |
| REGN | ▲ Buy | Option Exercise | 7,000 | $2.8M | 8/23/2023 | View on chart |
| REGN | ▼ Sell | Open Market | 2,192 | $1.8M | 3/23/2023 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 3,286 | $2.5M | 2/3/2023 | View on chart |
| REGN | ▲ Buy | Option Exercise | 5,000 | $1.4M | 2/3/2023 | View on chart |
| REGN | ▲ Buy | Grant | 1,926 | $0 | 12/16/2022 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 247 | $186K | 12/9/2022 | View on chart |
| REGN | ▼ Sell | Gift | 435 | $0 | 10/26/2022 | View on chart |
| REGN | ▼ Sell | Gift | 871 | $0 | 10/26/2022 | View on chart |
| REGN | ▼ Sell | Gift | 436 | $0 | 10/26/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 1,844 | $1.4M | 10/5/2022 | View on chart |
| REGN | ▼ Sell | Open Market | 3,346 | $2.4M | 10/3/2022 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 3,451 | $2.5M | 4/8/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 2,450 | $1.4M | 4/8/2022 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 2,155 | $1.6M | 4/8/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 5,000 | $1.4M | 4/8/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 2,000 | $1.1M | 3/31/2022 | View on chart |
| REGN | ▲ Buy | Option Exercise | 10,000 | $2.7M | 3/31/2022 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 1,797 | $1.3M | 3/31/2022 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 6,857 | $4.8M | 3/31/2022 | View on chart |
| REGN | ▼ Sell | Tax Withholding | 270 | $179K | 12/11/2021 | View on chart |
| REGN | ▲ Buy | Grant | 1,859 | $0 | 12/8/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 4,576 | $3.0M | 8/23/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 9 | $6K | 8/23/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 23 | $15K | 8/23/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 88 | $58K | 8/23/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 1 | $663 | 8/23/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 70 | $46K | 8/23/2021 | View on chart |
| REGN | ▼ Sell | Open Market | 14 | $9K | 8/23/2021 | View on chart |
| REGN | ▲ Buy | Option Exercise | 13,500 | $2.4M | 8/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock
Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock. Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.